Achondroplasia
by
Baujat G, Legeai-Mallet L, Finidori G,
Cormier-Daire V, Le Merrer M.
Hôpital Necker-Enfants Malades,
149 rue de Sèvres,
75743 Paris Cedex 15, France.
Best Pract Res Clin Rheumatol. 2008 Mar;22(1):3-18.

ABSTRACT

Achondroplasia (MIM 100800) is the most common non-lethal skeletal dysplasia. Its incidence is between one in 10,000 and one in 30,000. The phenotype is characterized by rhizomelic disproportionate short stature, enlarged head, midface hypoplasia, short hands and lordotic lumbar spine, associated with normal cognitive development. This autosomal-dominant disorder is caused by a gain-of-function mutation in the gene encoding the type 3 receptor for fibroblast growth factor (FGFR3); in more than 95% of cases, the mutation is G380R. The diagnosis is suspected on physical examination and confirmed by different age-related radiological features. Anticipatory and management care by a multidisciplinary team will prevent and treat complications, including cervical cord compression, conductive hearing loss and thoracolumbar gibbosity. Weight counselling, psychosocial guidance and professional integration programmes play an important role in the global quality of life of these patients and their families.

Achondroplasia
Genospirituality
'Artificial' evolution
Genetic enhancement
Germline genetic engineering
Congenital insensitivity to pain
Mood genes and human nature
Preimplantation genetic diagnosis
Origin and causes of achondroplasia

Refs
and further reading

HOME
Resources
Wireheading
BLTC Research
nootropic.com
Superhappiness?
Utopian Surgery?
The Good Drug Guide
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
MDMA: Utopian Pharmacology
Critique of Huxley's Brave New World